Zacks Investment Research downgraded Zogenix, Inc. (NASDAQ:ZGNX) to Sell in a report released today.
- Updated: October 12, 2016
Zacks Investment Research has downgraded Zogenix, Inc. (NASDAQ:ZGNX) to Sell in a report released on 10/12/2016.
Previously on Tuesday October 04, 2016, Leerink Swann reported about Zogenix, Inc. (NASDAQ:ZGNX) raised the target price from $0.00 to $17.00. At the time, this indicated a possible upside of 0.53%.
Yesterday Zogenix, Inc. (NASDAQ:ZGNX) traded -6.57% lower at $9.42. The company’s 50-day moving average is $9.69 and its 200-day moving average is $9.54. The last closing price is down -1.58% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 159,661 shares of the stock traded hands, down from an average trading volume of 168,723
See Chart Below
Zogenix, Inc. has a 52 week low of $7.33 and a 52 week high of $16.56 The company’s market cap is currently $0.
General Information About Zogenix, Inc. (NASDAQ:ZGNX)
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company's areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.